This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 Cancer Drug Stocks to Know Right Now

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Johnson & Johnson (JNJ - Get Report)

ASCO presentation: Phase III study of Zytiga in "pre-chemo" prostate cancer patients.

What we already know: Zytiga significantly delayed tumor progression in prostate cancer patients who have not been treated with chemotherapy. Zytiga also helped these patients live longer, although the survival benefit was not statistically significant. Based on these positive results, independent data monitors stopped the study early.

Key questions: What was the magnitude of benefit provided by Zytiga? In particular, what does the survival benefit trend look like and might it become statistically significant on longer follow up?

Other notes: At this point, the Zytiga study is the biggest attention grabber at ASCO from a Wall Street perspective because the results have far-reaching impact not only on J&J but prostate cancer drug competitors Medivation (MDVN) and Dendreon (DNDN).

4 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ARRY $7.30 0.00%
ARIA $8.99 0.00%
CLDX $26.76 0.00%
JNJ $99.58 0.00%
ONTY $1.72 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs